曲妥珠单抗联合甲状腺全切除术治疗甲状腺癌的疗效及对患者炎症因子的影响

doi:10.3969/j.issn.1671-7171.2020.07.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨曲妥珠单抗联合甲状腺全切除术治疗甲状腺癌的疗效及对患者炎症因子的影响。【方法】本院收治的甲状腺癌患者120例,随机分为两组,对照组患者单纯应用甲状腺全切除术进行治疗,观察组患者在对照组的基础上联合曲妥珠单抗进行治疗,比较两组患者临床疗效、术后情况及术后并发症;同时对比治疗前后患者炎症因子[血清趋化因子配体18(CCL-18)、白细胞介素-6(IL-6)]水平变化。【结果】观察组临床治疗有效率为98.3%(59/60),明显高于对照组的75.0%(45/60)(P<0.05);观察组患者的术后平均住院时间、平均镇痛时间、术后12 h和24 h视觉模拟评分(VAS)均低于对照组(P<0.05);治疗后两组患者血清CCL-18、IL-6水平较治疗前均有所下降,但观察组患者下降更为显著(P<0.05);两组患者治疗后并发症发生率相比较差异无显著性(P>0.05)。【结论】对甲状腺癌患者采用曲妥珠单抗联合甲状腺全切除术进行治疗临床效果较为显著,可有效控制患者血清CCL-18、IL-6水平,缩短住院时间和镇痛时间,降低术后并发症以及复发的概率,值得在临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	江波涛
	杨培丽
	徐安霞

关键词 ：甲状腺肿瘤/外科学, 甲状腺切除术, 抗体,单克隆/治疗应用

Abstract：【Objective】 To explore the effectiveness of trastuzumab in combination with total thyroidectomy in the surgical treatment of thyroid cancer an influence on serum inflammatory cytokines. 【Methods】 A total of 120 patients with thyroid cancer in our hospital were selected and divided into two groups. Patients in the control group received total thyroidectomy, while patients in the observation group received both thyroidectomy and trastuzumab treatment. The clinical effectiveness, hospital stay time after the operation, complications and serum level of inflammatory cytokines (CCL-18 and IL-6) were compared between the two groups. 【Results】 The rate of clinical effectiveness in the observation group was 98.3%(59/60),which was significantly higher than that in the control group [75.0%(45/60)](P<0.05). The average postoperative analgesia and hospital stay, VAS score at 12h and 24h after the operation in the observation group were all significantly lower than those in the control group(P<0.05). The levels of serum CCL-18 and IL-6 were significantly lower in the two groups after the treatment, while the observation group had significantly better results compared to the control group(P<0.05). There was no significant difference in the rate of complications between the two groups(P>0.05). 【Conclusion】 Trastuzumab in combination with total thyroidectomy in the surgical treatment of thyroid cancer has good clinical effect, which can lower serum level of CCL-18 and IL-6, shorten postoperative analgesia and hospital stay, decrease the risk of complications, It should be widely used in clinic.

Key words： hyroid Neoplasms/SU Thyroidectomy Antibodies,Monoclonal/TU

收稿日期: 2019-01-18

PACS:

R736.1

基金资助:四川省卫生厅科研课题(编号:070091)

引用本文:

江波涛, 杨培丽, 徐安霞. 曲妥珠单抗联合甲状腺全切除术治疗甲状腺癌的疗效及对患者炎症因子的影响[J]. 医学临床研究, 2020, 37(7): 1002-1004.
JIANG Bo-tao, YANG Pei-li, XU An-xia. Effectiveness of Trastuzumab in Combination with Total Thyroidectomy in the Surgical Treatment of Thyroid Cancer and Influence on Inflammatory Cytokines. JOURNAL OF CLINICAL RESEARCH, 2020, 37(7): 1002-1004.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.07.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I7/1002